

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_88133
Title of the Manuscript:	Discriminating Benign and Malignant Brain Tumors By Spectral Analysis of Cerebrospinal Fluid
Type of the Article	ORIGINAL RESEARCH ARTICLE

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljpri.com/index.php/JPRI/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<ol style="list-style-type: none"> 1. Firstly in this short study, the CSF does not endorse any treatments, procedures, products or physicians referenced in these patient fact sheets. This information is provided as an educational service and is not intended to serve as medical advice. 2 Investigational Therapies are many types of new therapies currently are being not studied in this short, especially on tumors for which the prognosis is generally poor through existing conventional therapies. In this discussion it is unknown whether these therapies will work and therefore the long term efficacy has not been established and discussed in detail as it is required in this study. 3. Results of FSD and FTDS would have expressed in the form of tables and graphical representation would be much more focussing attention to the readers. 	
Minor REVISION comments	<ol style="list-style-type: none"> 1. Authors of this current study, might have tested the levels of several candidate CNS in the CSF of patients with SFS and compared them with those of metastatic brain cancers and a variety of nonneoplastic CNS diseases so that they can determined empirically by trial and error for a given set of experimental protocols. 2. This study examines the current scientific knowledge about the biochemical elements in the CSF that have not been reported in the literature as brain cancer biomarkers and highlight reasons why the role of most markers is not yet established in the management of CNS tumors? 	
Optional/General comments	At the end of the conclusion, authors are not shown clear idea that profiling as of the soluble markers of the CSF is likely to become important in the future, but it is too early to say which method will prove most reliable in attaining that end.	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Tiruvedula Gopi Krishna
Department, University & Country	Adama Science and Technology University, Ethiopia